Berman Capital Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Berman Capital Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$15K	Hold	566	–	–	﹤0.01%	1078
2021 Q2	$16K	Buy	566 +17	+3%	+$490	﹤0.01%	994
2021 Q1	$15K	Sell	549 -14	-2%	-$387	﹤0.01%	908
2020 Q4	$15K	Hold	563	–	–	﹤0.01%	771
2020 Q3	$14K	Hold	563	–	–	﹤0.01%	702
2020 Q2	$13K	Buy	563 +92	+20%	+$1.82K	﹤0.01%	680
2020 Q1	$6K	Hold	471	–	–	﹤0.01%	860
2019 Q4	$7K	Hold	471	–	–	﹤0.01%	894
2019 Q3	$6K	Buy	+471	New	+$5.76K	﹤0.01%	914

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berman Capital Advisors's RVNC Position: Q3 2021 in Review

Berman Capital Advisors held its Revance Therapeutics, Inc. (RVNC) position steady in Q3 2021 at 566 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

Berman Capital Advisors first reported a position in RVNC in Q3 2019 and has held it in 9 quarters since. The position peaked at $16K in Q2 2021. 158 funds tracked by Wall St. Rank hold RVNC as of Q3 2021.

Berman Capital Advisors held 566 shares of Revance Therapeutics, Inc. worth $15K as of Q3 2021.
Berman Capital Advisors left its Revance Therapeutics, Inc. share count unchanged in Q3 2021.
Revance Therapeutics, Inc. made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1078 holding.
Berman Capital Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2019 and has held it in 9 quarters since.
Berman Capital Advisors's Revance Therapeutics, Inc. position peaked at $16K in Q2 2021.
158 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.